Mirati Therapeutics Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-34
RECRUITING3
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO86%
Delay Index: of 7 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +20.0 months). See all sponsors →
Open Mirati Therapeutics Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| KRYSTAL-12 NCT04685135 |
P3 | Active, not recruiting | Metastatic Non Small Cell Lung Cancer; Advanced Non Small Cell Lung Cancer | 453 | 2023-12-30 (+13 mo) |
| MRTX849 NCT04793958 |
P3 | Active, not recruiting | Advanced Colorectal Cancer; Metastatic Colorectal Cancer | 461 | 2026-01-16 (+28 mo) |
| MRTX849 NCT03785249 |
P1/2 | Active, not recruiting | Advanced Cancer; Metastatic Cancer | 731 | 2026-06-23 (+75 mo) |
| Adagrasib oral dose of 400 mg twice daily tablets NCT05609578 |
P2 | Active, not recruiting | Advanced NSCLC; Metastatic Lung Cancer | 90 | 2026-09-30 (+15 mo) |
| Adagrasib NCT05853575 |
P2 | Active, not recruiting | Advanced Cancer; Metastatic Cancer | 200 | 2026-10-30 (+20 mo) |
| Adagrasib NCT07415031 |
P2 | Recruiting | Solid Tumors | 170 | 2028-02-16 |
| Adagrasib NCT04613596 |
P2/3 | Recruiting | Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer | 626 | 2028-10-31 (+72 mo) |
| Adagrasib NCT06875310 |
P3 | Recruiting | Carcinoma, Non-Small-Cell Lung | 630 | 2029-09-07 |